Study of sacituzumab govitecan for advanced or non-removable bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests sacituzumab govitecan, an anti-cancer drug, for people with urothelial (bladder/urinary tract) cancer that has spread or can’t be removed with surgery. It’s designed for tumors that have been treated already in specific ways, to see if the medicine can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older (19+ for South Korea).
- You are well enough for treatment, with performance status 0 or 1.
- Your kidneys and liver tests are strong enough for treatment, based on study lab cutoffs.
- Your blood counts are adequate without needing transfusions (blood/hematology requirements).
- You have cancer expected to be treatable with a life expectancy of about 3 months or more.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
This trial tests a combination of two drugs, sacituzumab govitecan and zimberelimab, to treat muscle-invasive bladder cancer without removing the bladder. It's for patients who cannot or choose not to have bladder removal surgery or standard chemotherapy.
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
This Phase 1 study tests whether a new bladder-cancer treatment plan—radiation given at the same time as sacituzumab govitecan—can help people with muscle-invasive bladder cancer without starting with traditional chemo/radiation. Because it’s early-stage, the main goal is safety and learning the best way to use this combination to preserve the bladder.
Hear when a new Metastatic Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.